In AD transgenic mice, peripheral TNF-α blockage by the TNFR-Fc fusion protein (etanercept) reduces neuroinflammation, BBB disruption, and AD pathology [139]. This evidence concerns the gene TNFRSF1A and Alzheimer disease.